{"filings":[{"id":3182156,"accession_number":"0001193125-26-409169","cik":1658678,"company_name":"BioStem Technologies, Inc.","ticker":"BSEM","form_type":"8-K","filed_at":"2026-09-30T20:48:24+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"BioStem raises $3M private placement at $4.08/share; $10M BioTissue clearance payment due Sept 15 unpaid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 735,296 shares at $4.08 plus Series A and Series B warrants for 735,296 shares each at $3.83; aggregate gross proceeds ~$3.0 million; closed September 30, 2026.","Series A warrants expire five years and Series B warrants 24 months after effectiveness of the resale registration statement; full cash exercise would add roughly $5.6 million.","H.C. Wainwright & Co. is exclusive placement agent, receiving a 7.0% cash fee plus 18,382 placement agent warrants exercisable at $6.12 per share.","$10.0M Clearance Payment to BioTissue for Catalyze 510(k) clearance (received June 2026) was due Sept 15, 2026 and remains unpaid; company in talks on timing and terms.","Resale registration statement due within 30 days, effectiveness targeted within 45 days (75 if SEC full review); warrants carry 4.99%/9.99% beneficial ownership blockers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2961803,"accession_number":"0001193125-26-395556","cik":1658678,"company_name":"BioStem Technologies, Inc.","ticker":"BSEM","form_type":"8-K","filed_at":"2026-09-18T20:15:16+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioStem secures up to $40M committed equity facility with Roth Principal Investments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Facility allows BioStem to sell up to $40M shares at its discretion over a 36-month term.","Market Open/Intraday purchases priced at 3% VWAP discount; Pre/Post-Market at 5% discount.","Pays $400k cash commitment fee (1% of facility) plus $75k legal and $50k QIU fees.","Exchange cap of 19.99% (3,585,375 shares) unless avg price >=$4.3056 or shareholder approval.","Proceeds intended for working capital and general corporate purposes; no obligation to draw."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2219436,"accession_number":"0001193125-26-347211","cik":1658678,"company_name":"BioStem Technologies, Inc.","ticker":"BSEM","form_type":"8-K","filed_at":"2026-08-12T21:27:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.","GAAP net loss $9.0M ($0.52/share) vs income $10,613 in Q2 2025; adjusted EBITDA loss $4.6M.","Cash $7.0M at June 30, 2026 (from $13.7M); used $5.5M in ops; closed $2.5M private placement.","Resolved $5.3M debt via $3.5M cash and $1.0M promissory note; uplisted to Nasdaq Capital Market Aug 7, 2026.","Raises FY2026 revenue guidance to $26-29M from $25-29M; issued eight new U.S. design patents."],"consensus_eps_estimate":-0.51,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":14034779.0,"consensus_period":"2026-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2133357,"accession_number":"0001193125-26-340271","cik":1658678,"company_name":"BioStem Technologies, Inc.","ticker":"BSEM","form_type":"8-K","filed_at":"2026-08-07T20:15:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.","Trading transitions from OTCQB to Nasdaq effective at market open on Aug 7, 2026; ticker remains BSEM.","No shareholder action required; CEO Jason Matuszewski cites expanded capital access and liquidity.","Company is a regenerative medicine firm focused on perinatal tissue allograft products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}